Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Non Operating Income (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Non Operating Income for 6 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 18.73% to $10.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, up 47.53% year-over-year, with the annual reading at $44.0 million for FY2025, 47.53% up from the prior year.
  • Non Operating Income for Q4 2025 was $10.5 million at Janux Therapeutics, down from $10.9 million in the prior quarter.
  • The five-year high for Non Operating Income was $11.4 million in Q1 2025, with the low at $46000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $4.9 million, with a median of $4.2 million recorded in 2023.
  • The sharpest move saw Non Operating Income soared 2874.32% in 2022, then grew 18.73% in 2025.
  • Over 5 years, Non Operating Income stood at $74000.0 in 2021, then skyrocketed by 2874.32% to $2.2 million in 2022, then skyrocketed by 98.96% to $4.4 million in 2023, then skyrocketed by 101.1% to $8.8 million in 2024, then increased by 18.73% to $10.5 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $10.5 million, $10.9 million, and $11.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.